Thus, subcutaneous injection of Caspr1(203–355) peptides specifically act on the initial entry step of bacteria into the CNS, i.e, the penetration of bacteria through the BBB, to reduce the occurrence of E. coli meningitis. This evidence concerns the gene CNTNAP1 and meningitis.